secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001193125-25-272423
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request
--------------------------------------------------------------------------------

- FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.
- Clinical hold based on data previously reviewed by DSMB in summer 2025; DSMB found acceptable safety profile for expansion cohorts.
- TN-201 generally well tolerated; no new meaningful safety events since DSMB review.
- Tenaya working collaboratively with FDA to resolve hold; expects no impact on data milestones or development timelines.
- Company intends to resume dosing once protocol changes are implemented at trial sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525272423/0001193125-25-272423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525272423/tnya-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-272423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer